Pacific Biosciences Of Stock Performance
| PACB Stock | USD 1.30 0.04 3.17% |
The company holds a Beta of 1.2, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pacific Biosciences will likely underperform. At this point, Pacific Biosciences has a negative expected return of -0.49%. Please make sure to check Pacific Biosciences' standard deviation, maximum drawdown, kurtosis, as well as the relationship between the total risk alpha and potential upside , to decide if Pacific Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Pacific Biosciences of has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Disposition of 25000 shares by Mohr Marshall of Pacific Biosciences at 4.45 subject to Rule 16b-3 | 12/27/2024 |
2 | PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay ... | 01/08/2025 |
3 | Acquisition by Ordonez Kathy of 32179 shares of Pacific Biosciences at 1.65 subject to Rule 16b-3 | 01/23/2025 |
4 | Pacific Biosciences of California Stock Moves -1.18 percent What You Should Know | 01/27/2025 |
5 | Pacific Biosciences of California Inc Q4 2024 Earnings Report Preview What To Expect | 02/12/2025 |
6 | Disposition of 259909 shares by Henry Christian O of Pacific Biosciences at 1.878 subject to Rule 16b-3 | 02/18/2025 |
7 | PacBio to Participate in TD Cowens 45th Annual Health Care Conference | 02/19/2025 |
8 | Pacific Biosciences of California, Inc. Given Consensus Rating of Moderate Buy by Brokerages | 02/24/2025 |
9 | Neurogenomics Market Trends Analysis and Global Forecasts Report 2024-2031 Emerging Markets and Increased Awareness Create Opportunities, Declining Sequencing C... | 02/28/2025 |
10 | Disposition of 2973 shares by Farmer Michele of Pacific Biosciences at 1.407 subject to Rule 16b-3 | 03/03/2025 |
11 | Pacific Biosciences of California Increases Yet Falls Behind Market What Investors Need to Know | 03/14/2025 |
12 | Scientists Solve One of Genomics Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes | 03/17/2025 |
13 | Is Pacific Biosciences of California, Inc. the Most Volatile Stock Under 3 For Day Trading | 03/18/2025 |
14 | Pacific Biosciences of California Advances While Market Declines Some Information for Investors | 03/20/2025 |
15 | Acquisition by Van Oene Mark of 449176 shares of Pacific Biosciences subject to Rule 16b-3 | 03/21/2025 |
16 | Acquisition by Mohr Marshall of 32179 shares of Pacific Biosciences at 1.65 subject to Rule 16b-3 | 03/24/2025 |
| Begin Period Cash Flow | 182.6 M |
Pacific |
Pacific Biosciences Relative Risk vs. Return Landscape
If you would invest 195.00 in Pacific Biosciences of on December 24, 2024 and sell it today you would lose (65.00) from holding Pacific Biosciences of or give up 33.33% of portfolio value over 90 days. Pacific Biosciences of is currently does not generate positive expected returns and assumes 6.0799% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Pacific, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pacific Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pacific Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pacific Biosciences of, and traders can use it to determine the average amount a Pacific Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.08
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PACB |
Estimated Market Risk
| 6.08 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pacific Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pacific Biosciences by adding Pacific Biosciences to a well-diversified portfolio.
Pacific Biosciences Fundamentals Growth
Pacific Stock prices reflect investors' perceptions of the future prospects and financial health of Pacific Biosciences, and Pacific Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pacific Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (2.01) % | ||||
| Operating Margin | (2.28) % | ||||
| Current Valuation | 666.73 M | ||||
| Shares Outstanding | 297.85 M | ||||
| Price To Earning | 197.88 X | ||||
| Price To Book | 0.76 X | ||||
| Price To Sales | 2.51 X | ||||
| Revenue | 154.01 M | ||||
| Gross Profit | 47.67 M | ||||
| EBITDA | (356.38 M) | ||||
| Net Income | (309.85 M) | ||||
| Cash And Equivalents | 834.34 M | ||||
| Cash Per Share | 3.69 X | ||||
| Total Debt | 672.43 M | ||||
| Debt To Equity | 1.51 % | ||||
| Current Ratio | 11.19 X | ||||
| Book Value Per Share | 1.72 X | ||||
| Cash Flow From Operations | (206.06 M) | ||||
| Earnings Per Share | (1.59) X | ||||
| Market Capitalization | 387.21 M | ||||
| Total Asset | 1.26 B | ||||
| Retained Earnings | (2.15 B) | ||||
| Working Capital | 429.38 M | ||||
| Current Asset | 110.54 M | ||||
| Current Liabilities | 38.18 M | ||||
About Pacific Biosciences Performance
By analyzing Pacific Biosciences' fundamental ratios, stakeholders can gain valuable insights into Pacific Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pacific Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pacific Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 183.72 | 161.88 | |
| Return On Tangible Assets | (0.56) | (0.59) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | (0.61) | (0.64) |
Things to note about Pacific Biosciences performance evaluation
Checking the ongoing alerts about Pacific Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pacific Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pacific Biosciences generated a negative expected return over the last 90 days | |
| Pacific Biosciences has high historical volatility and very poor performance | |
| Pacific Biosciences may become a speculative penny stock | |
| Pacific Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 154.01 M. Net Loss for the year was (309.85 M) with profit before overhead, payroll, taxes, and interest of 47.67 M. | |
| Pacific Biosciences of currently holds about 834.34 M in cash with (206.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Pacific Biosciences of California Advances While Market Declines Some Information for Investors |
- Analyzing Pacific Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pacific Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Pacific Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pacific Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pacific Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pacific Biosciences' stock. These opinions can provide insight into Pacific Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pacific Stock analysis
When running Pacific Biosciences' price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |